Silence Therapeutics plc develops siRNA therapies through its proprietary mRNAi GOLD platform and trades in the U.S. through American Depositary Shares under SLN. Company news commonly covers clinical and preclinical updates for RNA-silencing programs in cardiovascular disease, hematology and rare diseases, along with financial results, research presentations and collaboration activity.
Recurring pipeline coverage centers on divesiran, a wholly owned siRNA candidate targeting TMPRSS6 for polycythemia vera, including SANRECO study updates and its FDA Fast Track and Orphan Drug designations. Updates also address platform-derived programs such as SLN312, AstraZeneca collaboration matters, balance-sheet commentary and board or executive changes.
Silence Therapeutics plc (Nasdaq: SLN) announced that Giles Campion, MD, will participate in a fireside chat at the Chardan Genetic Medicines Conference on October 4 at 3:45 p.m. ET in New York. The event can be viewed live on the company's website. Silence Therapeutics focuses on developing innovative siRNA therapeutics targeting diseases with significant unmet medical needs, leveraging its mRNAi GOLD™ platform. Major products include SLN360 for cardiovascular risk and SLN124 for rare hematological diseases. Collaborations with AstraZeneca and others enhance their research efforts.
Silence Therapeutics, a leader in RNAi therapeutics, announced participation in two upcoming conferences in New York. The first is the Morgan Stanley Global Healthcare Conference, featuring a fireside chat on September 13, 2022, at 5:15 p.m. ET. The second is the H.C. Wainwright Global Investment Conference, with a fireside chat on September 14, 2022, at 4:00 p.m. ET. Investors can access webcasts of these chats on the company’s website. Silence focuses on developing siRNA therapeutics targeting diseases with significant unmet needs.
Silence Therapeutics has received Fast Track Designation from the FDA for SLN124, an siRNA targeting the TMPRSS6 gene, aimed at treating polycythemia vera (PV). This designation could accelerate the development and review process, enabling quicker patient access to treatments. SLN124 has shown proof of mechanism and tolerability in prior studies. The company also plans to initiate a phase 1/2 study this year and is evaluating SLN124 for other hematological diseases.
Silence Therapeutics plc (NASDAQ: SLN) announced pricing for an underwritten offering of 5,950,000 American Depositary Shares (ADSs) at $9.50 each, yielding approximately $56.5 million before expenses. The offering aims to fund clinical trials, including Phase 2 SLN360 for ASCVD and Phase 1/2 SLN124 for polycythemia vera. The offering is expected to close around August 16, 2022. Morgan Stanley and William Blair are joint book-running managers. Silence's focus is on RNA interference therapeutics targeting significant unmet medical needs.
Silence Therapeutics plc, a leader in siRNA therapeutics, announced its participation in the Jefferies Healthcare Conference on June 9, 2022, at 10:00 a.m. EDT / 2:00 p.m. GMT. The presentation will be accessible via a live webcast on the company’s website, with an archived replay available afterward. Silence is focused on RNA interference technology to develop treatments for diseases, with key products including SLN360 for cardiovascular risk and SLN124 for hematological disorders. The company collaborates with AstraZeneca and others.
Silence Therapeutics plc (NASDAQ: SLN) announced its participation in a virtual fireside chat at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The on-demand presentation will be available on May 23 at 7:00 AM ET via the Silence website. Silence specializes in RNA interference (RNAi) therapeutics targeting significant unmet medical needs. Key candidates include SLN360 for cardiovascular risk reduction and SLN124 for hematological diseases. The Company collaborates with AstraZeneca and others to advance its innovative therapies.
Silence Therapeutics plc (NASDAQ: SLN) reported its Q1 2022 financial results, highlighting progress in its development pipeline. Key achievements include positive SLN360 data presented at ACC and FDA orphan drug designation for SLN124. Financially, the company generated £5.7 million in revenue, up from £3.1 million in Q1 2021, while net loss decreased to £7.7 million from £8.4 million. As of March 31, 2022, cash and equivalents totaled £59.3 million. The company anticipates further milestones, including durability data for SLN360 and topline results for SLN124, both expected in Q3 2022.
Silence Therapeutics plc (Nasdaq: SLN) announced a $2.0 million cash payment from Hansoh Pharmaceutical Group, following the achievement of a preclinical milestone in their collaboration established in October 2021. This deal involves developing siRNAs utilizing Silence’s mRNAi GOLD™ platform for three undisclosed targets. Silence has exclusive rights to two targets outside China, while Hansoh holds rights in China. Silence also stands to gain up to $1.3 billion in additional milestones and royalties from Hansoh's net product sales.
Silence Therapeutics, listed on Nasdaq as SLN, announced its participation in the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 8:00 a.m. Eastern Time. The presentation will focus on the company's innovative siRNA therapeutics aimed at treating unmet medical needs, including cardiovascular risks and rare hematological diseases. A live webcast will be available on the company’s website, followed by a replay. Silence leverages its proprietary mRNAi GOLD™ platform and collaborates with major industry players.
Silence Therapeutics announced results from the phase 1 APOLLO trial of SLN360, an siRNA targeting lipoprotein(a) (Lp(a)), presented at the ACC.22 event in Washington, D.C. The trial demonstrated a reduction of Lp(a) levels by up to 98% in healthy adults with elevated Lp(a). Results were published in the Journal of the American Medical Association, enhancing the visibility of their groundbreaking therapy aimed at decreasing heart disease risk. SLN360 is designed to temporarily block the LPA gene, potentially lowering the risk of heart attacks and strokes.